Daily haemodialysis improves indices of protein glycation

Nephrology Dialysis Transplantation

Volumn 17, Issue 5, 2002, Pages 871-878

  Floridi, Ardesio ^a   Antolini, Francesco ^a   Galli, Francesco ^a   Fagugli, Riccardo Maria ^b   Floridi, Emanuela ^a   Buoncristiani, Umberto ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Ospedale Silvestrini   (Italy)

Author keywords

AGEs; Daily hameodialysis; Furosine; Pentosidine; Protein glycation; Uraemic toxins

Indexed keywords

ADVANCED GLYCATION END PRODUCT; FUROSINE; PENTOSIDINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; FEMALE; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; KIDNEY FAILURE; MALE; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BINDING; PROTEIN GLYCOSYLATION;

EID: 0036092127     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.5.871     Document Type: Article

References (29)

1. New biomarkers of Maillard reaction damage to proteins
2. Pathogenic effects of advanced glycosylation: Biochemical, biologic and chemical implications for diabetes and aging
3. Protein modification by non enzymatic glucosylation: Possible role in the development of diabetic complications
4. Advanced glycosylation end-products in patients with diabetic nephropathy
5. Chromatographic quantitation of plasma and erythrocytes pentosidine in diabetic and uremic subjects
6. Immunological quantitation of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD
7. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure
8. Pathophysiology of advanced glycation end-products in renal failure
9. Involvement of 2-microglobulin modified with advanced glycation end-products in the pathogenesis of hemodialysis-associated amyloidosis
10. Site-specific modification of apolipoprotein B by advanced glycosylation end-products: Implication for lipoprotein clearance and atherogenesis
11. Advanced glycation end-products and atherosclerosis
12. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure
13. Analytical strategy for the assessment of the protein glycation status in uremic patients by high-performance liquid chromatography
14. Advanced protein glycosylation in diabetes and aging
15. Influence of hemodialysis membrane type on pentosidine plasma level, a marker of 'carbonyl stress'
16. Quantitative and qualitative assessment and clinical meaning of molecules removed with BK membranes
17. Daily dialysis: Long-term clinical metabolic results
18. Daily versus standard hemodialysis: One year experience
19. Daily home haemodialysis in the Netherlands: Effects on metabolic control, haemodynamics and quality of life
20. Optimal control of acid-base balance with daily hemodialysis
21. Erythrocyte glutathione S-transferase expression in uremic syndrome
22. Clinical and biochemical correlates of starting 'daily' hemodialysis
23. Left ventricular hypertrophy in daily dialysis
24. Aging of proteins: Isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose
25. Kinetic analysis of furosine and pentosidine in CAPD patients
26. Effect of phosphate on the kinetics and specificity of glycation of protein
27. Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal dialysis
28. Effect of a new vitamin E-coated membrane on glycoxidation during hemodialysis